DOCSLIB.ORG

Trends in Prescription Medication Use Among Children and Adolescents— United States, 1999-2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Trends in Prescription Medication Use Among Children and Adolescents— United States, 1999-2014 Supplementary Online Content Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents— United States, 1999-2014. JAMA. doi:10.1001/jama.2018.5690 eTable. Classification of Prescription Medications Reported by NHANES Participants Aged 0-19 Years From 1999- 2000 to 2013-2014 by Therapeutic Class This supplementary material was provided by the authors to give readers additional informtion about their work. © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 eTable. Classification of Prescription Medications Reported by NHANES Participants Aged 0-19 Years From 1999- 2000 to 2013-2014 by Therapeutic Class Therapeutic classes are based on the Lexicon Plus prescription medication database and only those classes reported in the manuscript are listed. ADHD Medications Antiadrenergic Agents, Centrally Acting Clonidine Guanfacine CNS Stimulants Amphetamines Amphetamine Amphetamine; Dextroamphetamine Dextroamphetamine Lisdexamfetamine Methylphenidate or Dexmethylphenidate Dexmethylphenidate Methylphenidate Other CNS Stimulant Pemoline Selective Norepinephrine Reuptake Inhibitor Atomoxetine Antibiotics Cephalosporins Cefadroxil Cephalexin Cefaclor Cefprozil Cefuroxime Loracarbef Cefdinir Cefditoren Cefixime Cefpodoxime Ceftibuten Ceftriaxone Glycopeptide Antibiotics Vancomycin H. Pylori Eradication Agents Amoxicillin; Clarithromycin; Lansoprazole Lincomycin Derivatives Clindamycin Macrolide Derivatives Telithromycin Azithromycin Clarithromycin Erythromycin Miscellaneous Antibiotics - Oral Chloramphenicol © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Erythromycin; Sulfisoxazole Metronidazole Sulfamethoxazole; Trimethoprim Penicillins Ambroxol; Amoxicillin Amoxicillin Ampicillin Amoxicillin; Clavulanate Penicillin Penicillin V Potassium Cloxacillin Dicloxacillin Oxacillin Quinolones Ciprofloxacin Levofloxacin Moxifloxacin Ofloxacin Sulfonamides - Oral Sulfamethoxazole Sulfamethoxazole; Trimethoprim Sulfisoxazole Tetracyclines Doxycycline Minocycline Tetracycline Urinary Anti-Infectives Methenamine Nitrofurantoin Trimethoprim Anticonvulsants Phenobarbital Primidone Clobazam Clonazepam Diazepam Lorazepam Felbamate Acetazolamide Topiramate Zonisamide Carbamazepine Oxcarbazepine Divalproex Sodium Valproic Acid Gabapentin Tiagabine Phenytoin Lacosamide Levetiracetam © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Ethosuximide Lamotrigine Antidepressants Antidepressants - Unspecified Miscellaneous Antidepressants Bupropion Monoamine Oxidase Inhibitors Monoamine Oxidase Inhibitors - Unspecified Phenylpiperazine Antidepressants Nefazodone Trazodone SSRI Antidepressants Desvenlafaxine Duloxetine Venlafaxine Citalopram Escitalopram Fluoxetine Fluvoxamine Paroxetine Sertraline Tetracyclic Antidepressants Mirtazapine Tricyclic Antidepressants Amitriptyline Clomipramine Desipramine Imipramine Nortriptyline Antidiabetic Agents Antidiabetic Agents - Unspecified Acarbose Metformin Insulin Insulin Aspart Insulin Aspart; Insulin Aspart Protamine Insulin Glargine Insulin Isophane (NPH) Insulin Lispro Insulin Lispro; Insulin Lispro Protamine Insulin Regular Repaglinide Glimepiride Pioglitazone Troglitazone Antihistamines Antihistamines - Unspecified Brompheniramine Carbinoxamine Cetirizine © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Clemastine Cyproheptadine Desloratadine Dexchlorpheniramine Diphenhydramine Fexofenadine Hydroxyzine Levocetirizine Loratadine Promethazine Triprolidine Antihypertensive Agents Antihypertensive Agents - Unspecified Angiotensin Converting Enzyme Inhibitors Captopril Enalapril Fosinopril Lisinopril Quinapril Angiotensin II Inhibitors Losartan Antihypertensive Combinations Amlodipine; Benazepril Hydrochlorothiazide; Lisinopril Hydrochlorothiazide; Spironolactone Hydrochlorothiazide; Triamterene Beta-Adrenergic Blocking Agents Atenolol Bisoprolol Metoprolol Carvedilol Nadolol Propranolol Sotalol Calcium Channel Blocking Agents Amlodipine Nifedipine Verapamil Diuretics Acetazolamide Furosemide Torsemide Spironolactone Chlorothiazide Hydrochlorothiazide Metolazone Antipsychotics Antipsychotics - Unspecified Aripiprazole Clozapine © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Olanzapine Paliperidone Quetiapine Risperidone Ziprasidone Haloperidol Lithium Prochlorperazine Thioridazine Anxiolytics, Sedatives, and Hypnotics Anxiolytics, Sedatives, and Hypnotics - Unspecified Butabarbital Butalbital Phenobarbital Alprazolam Clobazam Clonazepam Clorazepate Diazepam Lorazepam Triazolam Buspirone Chloral Hydrate Diphenhydramine Eszopiclone Hydroxyzine Zolpidem Asthma Medications Antiasthmatic Combinations - Unspecified Bronchodilators Albuterol Formoterol Levalbuterol Metaproterenol Pirbuterol Salmeterol Terbutaline Ipratropium Tiotropium Albuterol; Ipratropium Budesonide; Formoterol Fluticasone; Salmeterol Formoterol; Mometasone Aminophylline Theophylline Leukotriene Modifiers Montelukast Zafirlukast Inhaled Corticosteroids Beclomethasone © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Budesonide Ciclesonide Flunisolide Fluticasone Mometasone Mast Cell Stabilizers Cromolyn Contraceptives Contraceptives - Unspecified Desogestrel; Ethinyl Estradiol Dienogest; Estradiol Drospirenone; Ethinyl Estradiol Drospirenone; Ethinyl Estradiol; Levomefolate Estradiol; Medroxyprogesterone Ethinyl Estradiol; Ethynodiol Ethinyl Estradiol; Etonogestrel Ethinyl Estradiol; Levonorgestrel Ethinyl Estradiol; Norelgestromin Ethinyl Estradiol; Norethindrone Ethinyl Estradiol; Norgestimate Ethinyl Estradiol; Norgestrel Etonogestrel Medroxyprogesterone Norethindrone Glucocorticoids Betamethasone Budesonide Dexamethasone Hydrocortisone Methylprednisolone Prednisolone Prednisone Triamcinolone H2 Antagonists Cimetidine Famotidine Nizatidine Ranitidine Narcotic-Containing Analgesics Acetaminophen; Butalbital; Caffeine; Codeine Acetaminophen; Caffeine; Dihydrocodeine Acetaminophen; Codeine Acetaminophen; Hydrocodone Acetaminophen; Oxycodone Acetaminophen; Propoxyphene Codeine Fentanyl Hydrocodone Hydrocodone; Ibuprofen Meperidine © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Morphine Oxycodone Tramadol Proton Pump Inhibitors Dexlansoprazole Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole Topical Agents Topical Agents - Unspecified Anorectal Preparations Hydrocortisone; Pramoxine Topical Phenylephrine Topical Antiseptic And Germicides Chlorhexidine Topical Dermatological Agents Dermatological Agents - Unspecified Miscellaneous Topical Agents Aluminum Chloride Hexahydrate Topical Lactic Acid Topical Pimecrolimus Topical Selenium Sulfide Topical Tacrolimus Topical Topical Acne Agents Adapalene Topical Adapalene; Benzoyl Peroxide Topical Azelaic Acid Topical Benzoyl Peroxide Topical Benzoyl Peroxide; Clindamycin Topical Benzoyl Peroxide; Erythromycin Topical Clindamycin Topical Dapsone Topical Erythromycin Topical Salicylic Acid Topical Tretinoin Topical Topical Anesthetics Benzocaine Topical Lidocaine Topical Lidocaine; Prilocaine Topical Topical Anti-Infectives Imiquimod Topical Lindane Topical Malathion Topical Permethrin Topical Topical Anti-Rosacea Agents Azelaic Acid Topical Metronidazole Topical Topical Antibiotics © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Bacitracin Topical Erythromycin Topical Mupirocin Topical Neomycin; Polymyxin B Sulfate Topical Silver Sulfadiazine Topical Sulfacetamide Sodium Topical Sulfacetamide Sodium; Sulfur Topical Topical Antifungals Butenafine Topical Ciclopirox Topical Clotrimazole Topical Econazole Topical Ketoconazole Topical Miconazole Topical Miconazole; Zinc Oxide Topical Naftifine Topical Nystatin Topical Terbinafine Topical Topical Antineoplastics Imiquimod Topical Topical Antipsoriatics Tazarotene Topical Topical Antivirals Acyclovir Topical Penciclovir Topical Topical Depigmenting Agents Hydroquinone Topical Topical Emollients Ammonium Lactate Topical Emollients Topical Topical Keratolytics Salicylic Acid Topical Topical Steroids Alclometasone Topical Betamethasone Topical Clobetasol Topical Desonide Topical Desoximetasone Topical Diflorasone Topical Fluocinolone Topical Fluocinonide Topical Fluticasone Topical Hydrocortisone Topical Mometasone Topical Prednicarbate Topical Triamcinolone Topical Topical Steroids With Anti-Infectives Bacitracin; Hydrocortisone; Neomycin; Polymyxin B Topical Betamethasone; Clotrimazole Topical Nystatin; Triamcinolone Topical © 2018 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 Mouth And Throat Products Cetylpyridinium Topical Chlorhexidine Topical Mouth And Throat Products - Unspecified Nystatin Nasal Preparations Nasal Antihistamines And Decongestants Azelastine Nasal Cromolyn Nasal Ipratropium Nasal Naphazoline Nasal Olopatadine Nasal Nasal Steroids Beclomethasone Nasal Budesonide Nasal Ciclesonide Nasal Flunisolide Nasal Fluticasone Nasal Mometasone Nasal Triamcinolone Nasal Ophthalmic Preparations Ophthalmic Preparations - Unspecified Mydriatics Atropine Ophthalmic Ophthalmic Anesthetics Tetracaine Ophthalmic Ophthalmic Anti-Infectives Azithromycin
Load more

Recommended publications
  • More Than Expectorant: New Scientific Data on Ambroxol in the Context of the Treatment of Bronchopulmonary Diseases
    Mini Review iMedPub Journals Journal of Intensive and Critical Care 2017 www.imedpub.com ISSN 2471-8505 Vol. 3 No. 3: 37 DOI: 10.21767/2471-8505.100096 More than Expectorant: New Scientific Data Manuel Plomer1* and 2 on Ambroxol in the Context of the Treatment Justus de Zeeuw of Bronchopulmonary Diseases 1 Medical Affairs CHC Germany, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, D-65926, Frankfurt am Main, Deutschland, German Abstract 2 Medical Specialist for Internal Medicine, Pneumology and Sleep Medicine, Background:Ambroxol has been established for decades in the treatment of Cologne, Germany, German acute and chronic respiratory diseases. A reassessment of the benefit-risk was conducted recently. Objective: What new scientific data, relevant for the treatment of *Corresponding author: bronchopulmonary diseases, were published in the last decade? Dr. Manuel Plomer Method: Systematic literature search via http://www.pubmed.gov with the search term “ambroxol”, covering the publication period from 2006 to 2015. Non- [email protected] relevant publications were excluded manually. Medical Manager, Medical Affairs CHC Results: 64 relevant publications could be identified covering both, clinical and Germany, Sanofi-Aventis Deutschland GmbH, preclinical research. Industriepark Höchst, D-65926 Frankfurt am Conclusion: The traditional indication of ambroxol as an expectorant is confirmed Main, Germany. but new results revealed a better understanding of the various mechanisms of action of ambroxol and the benefits for special patient populations. The Tel: 49 69 305 36803 available data suggest the use of ambroxol as an adjuvant in anti-infective therapy, particularly in case of infections with biofilm-producing pathogens. Lung- protective properties are discussed in both infants and severely ill adult patients.
    [Show full text]
  • MSM Cross Reference Antihistamine Decongestant 20100701 Final Posted
    MISSISSIPPI DIVISION OF MEDICAID Antihistamine/Decongestant Product and Active Ingredient Cross-Reference List The agents listed below are the antihistamine/decongestant drug products listed in the Mississippi Medicaid Preferred Drug List (PDL). This is a cross-reference between the drug product name and its active ingredients to reference the antihistamine/decongestant portion of the PDL. For more information concerning the PDL, including non- preferred agents, the OTC formulary, and other specifics, please visit our website at www.medicaid.ms.gov. List Effective 07/16/10 Therapeutic Class Active Ingredients Preferred Non-Preferred ANTIHISTAMINES - 1ST GENERATION BROMPHENIRAMINE MALEATE BPM BROMAX BROMPHENIRAMINE MALEATE J-TAN PD BROMSPIRO LODRANE 24 LOHIST 12HR VAZOL BROMPHENIRAMINE TANNATE BROMPHENIRAMINE TANNATE J-TAN P-TEX BROMPHENIRAMINE/DIPHENHYDRAM ALA-HIST CARBINOXAMINE MALEATE CARBINOXAMINE MALEATE PALGIC CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE MALEATE CPM 12 CHLORPHENIRAMINE TANNATE ED CHLORPED ED-CHLOR-TAN MYCI CHLOR-TAN MYCI CHLORPED PEDIAPHYL TANAHIST-PD CLEMASTINE FUMARATE CLEMASTINE FUMARATE CYPROHEPTADINE HCL CYPROHEPTADINE HCL DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE MALEATE DIPHENHYDRAMINE HCL ALLERGY MEDICINE ALLERGY RELIEF BANOPHEN BENADRYL BENADRYL ALLERGY CHILDREN'S ALLERGY CHILDREN'S COLD & ALLERGY COMPLETE ALLERGY DIPHEDRYL DIPHENDRYL DIPHENHIST DIPHENHYDRAMINE HCL DYTUSS GENAHIST HYDRAMINE MEDI-PHEDRYL PHARBEDRYL Q-DRYL QUENALIN SILADRYL SILPHEN DIPHENHYDRAMINE TANNATE DIPHENMAX DOXYLAMINE SUCCINATE
    [Show full text]
  • European Journal of Scientific Exploration Vol 3 №2 2020
    EUROPEAN JOURNAL OF SCIENTIFIC EXPLORATION VOL 3 №2 2020 Determination of Oligomer Content in Benzonatate Drug Substance by HPLC Lakshmi Narasimha Rao Katakam 1 Santhosh Kumar Ettaboina 2 Thirupathi Dongala 2 1Saptalis Pharmaceuticals LLC, New York, USA 2Aurex Pharmaceuticals Inc, East Windsor, USA Abstract. A reverse-phase liquid chromatographic method has developed and validated to determine oligomer content in Benzonatate Drug substances. This method has a separation of relatively few monomer units, which constitutes an oligomer with a minimum adequate chromatographic resolution of 1.0 from each of the subject component peaks. The separation achieved using Phenomenex Luna C18 (250 X 4.6 mm) 5 µm column at a flow rate of 1.0 ml/min with an isocratic elution method. The mobile phase consisting of 0.25% Ammonium formate buffer and methanol in the ratio 350:650 (v/v), respectively. The Oligomer compounds detection carried out at UV 310 nm, and the LC method validated as per the current ICH Q2 guidelines. The method is effectively validated and proved to be precise, specific, linear, robust, and rugged to quantitate oligomer content in Benzonatate drug substance. Key words: benzonatate (BNZ), oligomers, HPLC, method validation. Introduction Benzonatate (BNZ) is an oral antitussive drug used to relieve and suppress cough in patients older than ten years of age (Oligomer Wikipedia, 2020). Currently, BNZ is the only non-narcotic antitussive available as a prescription drug. The chemical structure resembles that of the anesthetic agents in the para-amino-benzoic acid class (such as procaine and tetracaine), BNZ exhibits anesthetic or numbing action. BNZ also inhibits the transmission of impulses of the cough reflex in the medulla's vagal nuclei (Tessalon, 2020).
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • 2-Bromopyridine Safety Data Sheet Jubilant Ingrevia Limited
    2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) Date of Compilation : July 03 ’ 2019 Date of Revision : February 09 ’ 2021 Revision due date : January 2024 Revision Number : 01 Version Name : 0034Gj Ghs01 Div.3 sds 2-Bromopyridine Supersedes date : July 03 ’ 2019 Supersedes version : 0034Gj Ghs00 Div.3 sds 2-Bromopyridine Jubilant Ingrevia Limited Page 1 of 9 2-Bromopyridine Safety Data Sheet According to the federal final rule of hazard communication revised on 2012 (HazCom 2012) SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1. Product identifier PRODUCT NAME : 2-Bromopyridine CAS RN : 109-04-6 EC# : 203-641-6 SYNONYMS : 2-Pyridyl bromide, Pyridine, 2-bromo-, beta-Bromopyridine, o-Bromopyridine SYSTEMATIC NAME : 2-Bromopyridine, -Pyridine, 2-bromo- MOLECULAR FORMULA : C5H4BrN STRUCTURAL FORMULA N Br 1.2. Relevant identified uses of the substance or mixture and uses advised against 1.2.1. Relevant identified uses 2-Bromopyridine is used as an intermediate in the pharmaceutical industry for the manufacture of Atazanavir (an antiretroviral drug), Carbinoxamine, Chloropyramine, triprolidine (antihistamine drugs), Disopyramide Phosphate (an antiarrythmic drug), Mefloquine (antimalarial drug), Pipradrol (mild CNS stimulant) etc. Uses advised against: None 1.3. Details of the supplier of the safety data sheet Jubilant Ingrevia Limited REGISTERED & FACTORY OFFICE: Jubilant Ingrevia Limited Bhartiagram, Gajraula , District: Amroha, Uttar Pradesh-244223, India PHONE NO: +91-5924-252353 to 252360 Contact Department-Safety: Ext. 7424 , FAX NO : +91-5924-252352 HEAD OFFICE: Jubilant Ingrevia Limited, Plot 1-A, Sector 16-A,Institutional Area, Noida, Uttar Pradesh, 201301 - India T +91-120-4361000 - F +91-120-4234881 / 84 / 85 / 87 / 95 / 96 [email protected] -www.jubilantingrevia.com 1.4.
    [Show full text]
  • Product Information
    PRODUCT INFORMATION NAME OF THE MEDICINE POLARAMINE® (dexchlorpheniramine maleate) DESCRIPTION Polaramine (dexchlorpheniramine maleate) is the dextro-isomer of chlorpheniramine maleate. It is an antihistamine with anticholinergic properties Dexchlorpheniramine maleate (CAS no. 2438-32-6) is described chemically as (+)-2-[p- chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine maleate (1:1). It has the empirical formula of C16H19ClN2.C4H4O4 and the following structural formula: Dexchlorpheniramine maleate is a white, odourless, crystalline powder which in aqueous solution has a pH of between 4 and 5. It is freely soluble in water, soluble in alcohol and in chloroform, but only slightly soluble in benzene or ether. PHARMACOLOGY Pharmacodynamics Mechanism of Action: Dexchlorpheniramine, the d-isomer of the racemic compound chlorpheniramine, is two times more active than chlorpheniramine. Dexchlorpheniramine does not prevent the release of histamine, but rather, competes with free histamine for binding at the H1-receptor sites, and competitively antagonizes the effects of histamine on H1-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Blockade of H1-receptors also suppresses the formation of oedema, flare, and pruritus that result from histaminic activity. Since dexchlorpheniramine binds to central and peripheral H1-receptors, sedative effects are likely to occur. H1-antagonists are structurally similar to anticholinergic agents and therefore possess the potential to exhibit anticholinergic properties of varying
    [Show full text]
  • Report Update 1
    Drug Class Review on Newer Antihistamines Final Report Update 1 April 2006 Original Report Date: November 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior version of this report can be accessed at the DERP website. Final Report Update #1 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION.............................................................................................................................................................4 SCOPE AND KEY QUESTIONS.............................................................................................................................6
    [Show full text]
  • Research Article
    Volume 8, Issue 2, May – June 2011; Article-004 ISSN 0976 – 044X Research Article SPECTROPHOTOMETRIC SIMULTANEOUS ANALYSIS OF AMBROXOL HYDROCHLORIDE, GUAIFENESIN AND TERBUTALINE SULPHATE IN LIQUID DOSAGE FORM (SYRUP) Ritu Kimbahune*, Sunil K, Prachi Kabra, Kuldeep Delvadiya, Sanjay Surani Department of Quality Assurance, Nargund College of Pharmacy, Dattatreyanagar, Bangalore - 560 085, India. Accepted on: 06-03-2011; Finalized on: 28-05-2011. ABSTRACT This study proposes a method for simultaneous estimation of Ambroxol HCl, Guaifenesin and Terbutaline sulphate in syrup form. The study was done by combining three spectrophotometric methods viz use of specific absorbance [A 1%, 1cm], second order derivative and colorimetry. Absorption of Guaifenesin and Terbutaline sulphate were found to be zero at 307.5nm, thus enabling the measurement of Ambroxol HCl, using specific absorbance in zero order spectrum. Applying the second order derivative, the amplitude of Guaifenesin was measured at 279.4nm, while Ambroxol HCl and Terbutaline sulphate were at zero cross point. For colorimetric measurement of Terbutaline Sulphate, a colored substance was obtained by coupling the oxidized product of Terbutaline sulphate with 4-aminoantipyrine and its absorption was measured at 550nm. The proposed method was statistically validated in accordance with ICH guidelines and results were found to be satisfactory for accuracy, precision and specificity. Keywords: Ambroxol HCl, Guaifenesin and Terbutaline sulphate, second order derivative, colorimetric method. INTRODUCTION TBS as an individual drug or in combination, either in pure or in pharmaceutical forms as well as in biological Ambroxol hydrochloride (AB) [trans-4-[(2-amino-3,5- fluids and tissues. Literature survey reveals that there is dibromobenzyl)amino]cyclohexanol hydrochloride] is a no single spectrophotometric analysis reported for the semi-synthetic derivative of vasicine obtained from Indian determination of AB, GF and TBS simultaneously in liquid shrub Adhatodavasica.
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • Mail Order Maintenance Medication Exclusion List
    Maintenance Medication Exclusion List The following is a list of drugs that are excluded as maintenance medications. Medications which are listed here cannot be filled through the mail order pharmacy for the mail order incentive. This list includes both formulary/preferred and non-formulary/non-preferred medications, and does not provide information regarding the specific coverage, limitations, exclusions or quotas an individual member may have. Some dosage forms and strengths of a particular drug may be considered maintenance medications, whereas others may not. This list is sorted alphabetically by generic drug name. Generic drug names are written in lower case letters. Brand drug names (or some generic drugs with a trade name) are written in CAPITAL letters. Some drugs do not have a brand name available, in such cases the generic name is listed in the “Brand Name” column. This list of drugs should not be used to determine pharmacy benefits, such as prescription copay/coinsurance amounts or formulary status. If you have questions about the formulary status of a medication, or your prescription benefits, please call our Member Services Department at 1-888-681-7878 (toll free). For the hearing or speech impaired: 1-800-521-4874 (toll free TTY). The medications on this list are subject to change at any time. Exclusions: Any formulation that is required to be administered by a skilled medical professional or in a medical office, drugs infused in the home or in an infusion center, drugs that may have other quantity restrictions, any state law that may prohibit the mailing of certain dosage formulation of a drug, drugs that have a high potential for waste and diversion, drugs that require temperature control upon mailing and drugs that require refrigeration.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]